pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

forbius PRESS RELEASE ARCHIVE

Sep 21, 2020

Bristol Myers Squibb Completes Acquisition of Forbius

Aug 24, 2020

Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio

Nov 18, 2019

Forbius to Present at Jefferies 2019 London Healthcare Conference

Nov 8, 2019

Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC

Nov 5, 2019

SITC 2019: Forbius to Report Phase 1a Oncology Clinical Data with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor, in Late-Breaking Poster Presentation

Oct 14, 2019

Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor; Closes Series C Financing

Oct 10, 2019

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego

Sep 28, 2019

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor

Sep 23, 2019

Forbius Announces AVID200, a First-in-Class TGF-beta 1 and 3 Selective Inhibitor, to be Featured at ESMO and CICON 2019

Jun 4, 2019

Forbius to Present at Jefferies 2019 Healthcare Conference

Apr 24, 2019

Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor

Apr 22, 2019

Forbius Announces First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer (TNBC) Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC

Mar 29, 2019

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Mar 7, 2019

Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC

Mar 4, 2019

Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor

Feb 14, 2019

Forbius Announces a Clinical Trial Collaboration with the Myeloproliferative Neoplasm Research Consortium to Evaluate AVID200, a Novel TGF-beta Inhibitor, in Myelofibrosis

Jan 7, 2019

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200, a Novel TGF-beta 1 and 3 Inhibitor

Jan 2, 2019

Forbius to Present at the 37th Annual J.P. Morgan Healthcare Conference

Nov 26, 2018

Forbius’ AVID200, a novel TGF-beta 1 and 3 Inhibitor, Cleared by the FDA to Commence Phase 1 Clinical Trial in Solid Tumors

Oct 22, 2018

Forbius Announces First Patient Dosed in Phase 2 Trial of anti-EGFR ADC AVID100 in EGFR-Overexpressing Squamous NSCLC

Aug 24, 2018

Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas

Google Analytics Alternative